James Lau

James Lau

Auto-generated profile, based on publicly available information

James Lau

University of North Carolina at Chapel Hill School of Medicine, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2021 in Artificial Intelligence in Gastrointestinal Endoscopy
Verified
Journal Article
Open access
BYByung Soo Yoo
Byung Soo Yoo
SDSteve M D'Souza
Steve M D'Souza
KHKevin Houston
Kevin Houston
APAnkit Patel
Ankit Patel
JLJames Lau
James Lau
DJDavid Johnson
David Johnson
Artificial intelligence is a technology that processes and analyzes information with reproducibility and accuracy. Its application in medicine, especially in the field of gastroenterology, has great potential to facilitate in diagnosis of various disease states. Currently, the role of artificial intelligence as it pertains to colonoscopy revolves around enhanced polyp detection and characterization. The aim of this article is to review the current and potential future applications of artificial intelligence for enhanced quality of detection for colorectal neoplasia.

1 July 2025 in Journal of Primary Care & Community Health
Verified
Journal Article
Open access
IRIsabel Roth
Isabel Roth
PTPaula Tomczak
Paula Tomczak
ABAzeb Berhane
Azeb Berhane
JLJames Lau
James Lau
PGPaula Gardiner
Paula Gardiner
JLJennifer Leeman
Jennifer Leeman
Background: While biopsychosocial interventions are recommended for treatment of patients with chronic pain, outcome measurement frequently does not take a multifaceted approach to assessing patient outcomes. As primary care settings increasingly implement chronic pain approaches such as Integrative Group Medical Visits (IGMV), a comprehensive yet pragmatic measurement approach is needed to capture biopsychosocial outcomes. Methods: We recruited 21 clinicians, administrators, and staff with direct experience implementing IGMV in safety-net settings to participate in semi-structured qualitative interviews. Participants were recruited from 6 Federally-Qualified Health Centers and 4 Safety-Net Hospital outpatient clinics representing 6 states across the U.S. We first analyzed interview transcripts using the Consolidated Framework of Implementation Research, then used inductive thematic content analysis to identify themes related to what participants currently measure and the outcomes they view as important to be measuring. Results: Thematic content analysis revealed 3 themes: variability of measures chosen, rationale for measures chosen, and desire for biopsychosocial outcome measurement tailored to IGMV for chronic pain. Thirteen different measures were used across 9 sites. The choice of measures was driven by clinical utility and/or administrative incentives. Interviewees described that as patients progressed through IGMV they demonstrated improved health through improvements in social support, self-efficacy in pain management, self-management behaviors, and improved physical function. The measures currently used address most but not all these outcomes. Conclusion: We recommend developing and refining a biopsychosocial outcome measurement tool that addresses unique aspects of IGMV. These findings contribute to a growing consensus on how to measure actionable, patient-centered data on biopsychosocial interventions for chronic pain.

1 January 2017 in Endoscopic Ultrasound
Verified
Journal Article
Open access
Raymond TangRaymond Tang
Raymond Tang
JWJohn Wong
John Wong
MKMoe Kyaw
Moe Kyaw
ATAnthony YB Teoh
Anthony YB Teoh
YTYee-Kit Tse
Yee-Kit Tse
JLJames Lau
James Lau
Background and Objectives: Patients with hepatocellular carcinoma (HCC) or other malignancies with portal vein thrombosis (PVT) are at high risk for recurrent variceal bleeding. Recent evidence suggested that secondary prophylaxis (SP) for variceal bleeding may improve clinical outcomes. Methods: From 2014 to 2016, consecutive patients with HCC ± PVT or non-HCC malignancy + PVT with gastroesophageal variceal bleeding within 12 weeks were recruited for endoscopic ultrasound-guided cyanoacrylate injection (EUS-CYA) for SP. Varices = 3 mm on EUS were treated by EUS-CYA. Patients were followed up for 6 months after EUS or till death. A historical control group of HCC patients who underwent esophagogastroduodenoscopy-CYA (EGD-CYA) for index gastroesophageal variceal bleeding alone was identified in a prospective gastrointestinal bleed database from 2009 to 2013 for comparison. Results: Twenty-three patients underwent EUS-CYA for SP, while 33 HCC patients who underwent EGD-CYA for index variceal bleeding alone were identified as historical controls. In the EUS-CYA group, twenty patients had HCC + cirrhosis (85.0% also with PVT), while the other three patients had non-HCC malignancy + PVT. Majority of the HCC patients in both groups had Barcelona clinic liver cancer Stage C disease (85.0% vs. 75.8%, P = 0.421) and Child-Pugh Class B cirrhosis (55.0% vs. 71.4%, P = 0.241). Both the 30- and 90-day death adjusted cumulative incidence of rebleeding was significantly lower in the EUS-CYA group when compared to EGD-CYA control group (13% vs. 42% at 30-day, P = 0.023 and 22% vs. 61% at 90-day, P = 0.005, respectively). Conclusion: EUS-CYA for SP significantly reduces both the 30-day and 90-day death adjusted cumulative incidence of rebleeding in patients at high risk for recurrent gastroesophageal variceal bleeding when compared to EGD-CYA for index bleeding alone.